SynthesisPloS one2022
The invisible costs of obstructive sleep apnea (OSA): Systematic review and cost-of-illness analysis.
Synthesis in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06606691 (Wearable Technology in the Detection and Evaluation of Sleep-Related Breathing Disorders), which is not on this map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Wearable Technology in the Detection and Evaluation of Sleep-Related Breathing Disorders
Who cites it
53 citing papers in PubMed, 85 citations in OpenAlex.
- Exposure to environmental toxicants and obstructive sleep apnea: a cross-sectional study.Future science OA · 2026Article
- Association between ln(FPG/HDL-C) × BMI and self-reported obstructive sleep apnea: A cross-sectional study using NHANES data.Medicine · 2026Article
- Rethinking Long-Term Follow-Up of CPAP Therapy in Obstructive Sleep Apnea: Toward Personalized and Integrated Care.Healthcare (Basel, Switzerland) · 2026Review
- Investigating the Incremental Cost and Utilization Burden of Obstructive Sleep Apnea in Overweight to Severely Obese Patients.Diabetes, obesity & metabolism · 2026Article
- Targeting Hypoglossal Neurobiology in the Treatment of Obstructive Sleep Apnea: The Emergence of Aroxybutynin-Atomoxetine (AD109).Brain sciences · 2026Article
- Obstructive Sleep Apnea in Critically Ill Patients: A Structured Narrative Review of Prevalence, Diagnostic Barriers, and Clinical Implications in the ICU.Clocks & sleep · 2026Review
- Breathing bad: increased risk for obstructive sleep apnea in current and former smokers.Scientific reports · 2026Article
- Adherence to positive airway pressure therapy and healthcare resource utilization and costs among patients with obstructive sleep apnea and obesity.International journal of obesity (2005) · 2026Article
- Obstructive sleep apnea contributes to coronary artery disease development and poor prognosis.American journal of translational research · 2026Article
- Toward developing more effective screening questionnaires for obstructive sleep apnoea: a conceptual model and testing.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Article
- Effectiveness of Individualized Nursing in Perioperative Management of Patients With Obstructive Sleep Apnea: A Retrospective Cohort Study.Canadian respiratory journal · 2026Article
- Barriers and facilitators to weight loss in patients living with obesity and OSAHS: a qualitative study based on the Theoretical Domains Framework (TDF).Frontiers in medicine · 2026Article
- Effects of time-restricted eating on weight loss, sleep, and quality of life in obstructive sleep apnea-hypopnea syndrome (OSAHS) patients with obesity: a randomized controlled trial.Frontiers in nutrition · 2026Article
- A systematic review of obstructive sleep apnea in Indigenous peoples worldwide.Sleep advances : a journal of the Sleep Research Society · 2026Review
- Impact of obstructive sleep apnea-hypopnea syndrome severity on quality of life, anxiety disorders, and productivity in an active population.The Libyan journal of medicine · 2025Article
- Causal effect of potential risk factors on obstructive sleep apnea: a Mendelian randomization study.Future science OA · 2025Article
- Advancing Obstructive Sleep Apnea Management: Recent Trends from Conventional to Innovative Therapies.Journal of clinical medicine · 2025Review
- Respiratory muscle stiffness and the impact of PAP therapy in OSA: role of shear wave elastography.Sleep & breathing = Schlaf & Atmung · 2025Article
- Clinical and psychological predictors of obstructive sleep apnoea in an Australian adult population with severe and complex obesity.BMC psychology · 2025Article
- The Impact of Functional Jaw Orthopedics on Sleep-Related Breathing and Sleep-Related Bruxism: Case Series Study.Sleep science (Sao Paulo, Brazil) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundObstructive sleep apnea (OSA) is a risk factor for several diseases and is correlated with other non-medical consequences that increase the disease's clinical and economic burden. However, OSA's impact is highly underestimated, also due to substantial diagnosis gaps.
objectiveThis study aims at assessing the economic burden of OSA in the adult population in Italy by performing a cost-of-illness analysis with a societal perspective. In particular, we aimed at estimating the magnitude of the burden caused by conditions for which OSA is a proven risk factor.
methodsA systematic literature review on systematic reviews and meta-analyses, integrated by expert opinion, was performed to identify all clinical and non-clinical conditions significantly influenced by OSA. Using the Population Attributable Fraction methodology, a portion of their prevalence and costs was attributed to OSA. The total economic burden of OSA for the society was estimated by summing the costs of each condition influenced by the disease, the costs due to OSA's diagnosis and treatment and the economic value of quality of life lost due to OSA's undertreatment.
resultsTwenty-six clinical (e.g., diabetes) and non-clinical (e.g., car accidents) conditions were found to be significantly influenced by OSA, contributing to an economic burden ranging from €10.7 to €32.0 billion/year in Italy. The cost of impaired quality of life due to OSA undertreatment is between €2.8 and €9.0 billion/year. These costs are substantially higher than those currently borne to diagnose and treat OSA (€234 million/year).
conclusionsThis study demonstrates that the economic burden due to OSA is substantial, also due to low diagnosis and treatment rates. Providing reliable estimates of the economic impact of OSA at a societal level may increase awareness of the disease burden and help to guide evidence-based policies and prioritisation for healthcare, ultimately ensuring appropriate diagnostic and therapeutic pathways for patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.